Humanigen announces proposed public offering of five million ordinary shares

BURLINGAME, Calif .– (BUSINESS WIRE) – Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on the prevention and treatment of an immune hyperresponse known as a “cytokine storm” with its flagship drug candidate, lenzilumab^TM, today announced that it has launched a subscribed public offering of 5,000,000 shares of its ordinary shares. As part of this offer, Humanigen expects to grant the underwriters a 30-day option to purchase up to 750,000 additional common shares. The Offer is subject to market and other conditions, and there can be no assurance as to whether or when the Offer may be made or as to the actual size or terms of the Offer.

Jefferies, Credit Suisse and Cantor are acting as co-bookrunners for the offering. Bryan, Garnier & Co. acts as European lead manager of the offer, Oppenheimer & Co. acts as lead manager of the offer and HC Wainwright & Co., National Securities Corporation and Roth Capital Partners act as co-managers for the offer.

Humanigen intends to use the net proceeds of the offering for manufacturing and market preparation upon receipt of an emergency use authorization from the Food and Drug Administration for lenzilumab.^TM in COVID-19 hospital patients, as well as for working capital and other general corporate purposes.

A registration statement relating to the securities sold under the Offer has been declared effective by the Securities and Exchange Commission (the “SEC”). The securities will only be offered by means of a prospectus supplement and an attached prospectus forming part of the actual registration statement. A preliminary prospectus supplement relating to and describing the terms of the Offer will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offer may be obtained, when available, from Jefferies LLC, attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at [email protected] or by phone at (877) 821-7388; Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27650, by email at [email protected] or by phone at (800) 221 -1037; or Cantor Fitzgerald & Co., Attn .: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor any sale of securities in any state or jurisdiction where such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-looking statements

This press release contains forward-looking statements. Forward-looking statements reflect the current knowledge, assumptions, judgment and expectations of management regarding future performance or events. Although management believes that the expectations reflected in these statements are reasonable, they provide no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in forward-looking statements. Words such as “will”, “expect”, “intend”, “plan”, “potential”, “possible”, “goals”, “accelerate”, “continue” and similar expressions identify forward-looking statements. Examples of forward-looking statements in this press release include, without limitation, statements regarding the completion of the Offer, the terms of the Offer, the satisfaction of customary closing conditions with respect to the Offer and the ‘intended use of the net proceeds of the offering. . Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in periodic and other documents filed by the company with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. We assume no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unforeseen events, except as the law requires it.